NYSE · Healthcare · Diagnostics & Research · USA
Labcorp Holdings Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Labcorp Holdings Inc provides laboratory testing and drug development services globally to physicians, hospitals, health systems, pharmaceutical companies, and patients. The company operates through two segments: Diagnostics, offering routine and specialty testing through laboratory networks, and Biopharma and Laboratory Solutions, providing central laboratory and other testing services. Its services support healthcare decision-making and drug development across multiple countries worldwide.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Labcorp Holdings Inc stock.
Overvalued: intrinsic value $204.43 per share, market price $318.83, margin of safety -56.0% (as of 2026-10-19).
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $204.43; the price of $318.83 is 56% above that value, and 76% of that value comes from beyond year five.
Leak Score: 48/100 on 12 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
3 more in this industry show a wider margin of safety.
LH is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $204.43; the price of $318.83 is 56% above that value, and 76% of that value comes from beyond year five.
$204.43 per share (as of the 2026-10-19 close), against a market price of $318.83. That is a margin of safety of -56.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
48 out of 100, which we rate "On Watch", on 12 of 12 value investing signals.